EUVIMEDEUVIMED entdecken
Multizentrische Studie

Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study

Jeffrey D McCurdy, Javeria Munir, Simon Parlow, Jacqueline Reid, Russell Yanofsky, Talal Alenezi, Joseph Meserve, Brenda Becker, Zubin Lahijanian, Anas Hussam Eddin, Ranjeeta Mallick, Tim Ramsay und 8 weitere

Clinical Gastroenterology and Hepatology · 2024-05 · 22 (5) · 1058-1066.e2

DOI: 10.1016/j.cgh.2023.12.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-05. Verfasst von Jeffrey D McCurdy und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Cana…. Hauptthemen laut MEDLINE: Crohn Disease, Magnetic Resonance Imaging, Treatment Failure, Rectal Fistula. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Clinical and radiologic variables associated with perianal fistula (PAF) outcomes are poorly understood. We developed prediction models for anti-tumor necrosis factor (TNF) treatment failure in patients with Crohn's disease-related PAF. METHODS: In a multicenter retrospective study between 2005 and 2022 we included biologic-naive adults (>17 years) who initiated their first anti-TNF therapy for PAF after pelvic magnetic resonance imaging (MRI). Pretreatment MRI studies were prospectively reread centrally by blinded radiologists. We developed and internally validated a prediction model based on clinical and radiologic parameters to predict the likelihood of anti-TNF treatment failure, clinically, at 6 months. We compared our model and a simplified version of MRI parameters alone with existing imaging-based PAF activity indices (MAGNIFI-CD and modified Van Assche MRI scores) by De Long statistical test. RESULTS: We included 221 patients: 32 ± 14 years, 60% males, 76% complex fistulas; 68% treated with infliximab and 32% treated with adalimumab. Treatment failure occurred in 102 (46%) patients. Our prediction model included age at PAF diagnosis, time to initiate anti-TNF treatment, and smoking and 8 MRI characteristics (supra/extrasphincteric anatomy, fistula length >4.3 cm, primary tracts >1, secondary tracts >1, external openings >1, tract hyperintensity on T1-weighted imaging, horseshoe anatomy, and collections >1.3 cm). Our full and simplified MRI models had fair discriminatory capacity for anti-TNF treatment failure (concordance statistic, 0.67 and 0.65, respectively) and outperformed MAGNIFI-CD (P = .002 and < .0005) and modified Van Assche MRI scores (P < .0001 and < .0001), respectively. CONCLUSIONS: Our risk prediction models consisting of clinical and/or radiologic variables accurately predict treatment failure in patients with PAF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseMagnetic Resonance ImagingTreatment FailureRectal FistulaHumansMaleFemaleAdultRetrospective StudiesAdalimumabYoung AdultInfliximabMiddle AgedTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Stichwörter der Autor:innen

IBD ComplicationsPerianal Crohn’s DiseasePredictive Model

Substanzen

AdalimumabInfliximabTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: jmccurdy@toh.on.ca.
  • Division of Diagnostic Imaging, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Medicine, UBC, Vancouver, British Columbia, Canada.
  • Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California.

Förderung

  • Pfizer

Zitieren

APA

McCurdy, J. D., Munir, J., Parlow, S., Reid, J., Yanofsky, R., Alenezi, T., Meserve, J., Becker, B., Lahijanian, Z., Eddin, A. H., Mallick, R., Ramsay, T., Rosenfeld, G., Bessissow, A., Bessissow, T., Jairath, V., Singh, S., Bruining, D. H., Macdonald, B., & Canadian IBD Research Consortium (2024). Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.12.006

Vancouver

McCurdy JD, Munir J, Parlow S, Reid J, Yanofsky R, Alenezi T, et al. Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.12.006

BibTeX
@article{McCurdy2024,
  author = {McCurdy, Jeffrey D and Munir, Javeria and Parlow, Simon and Reid, Jacqueline and Yanofsky, Russell and Alenezi, Talal and Meserve, Joseph and Becker, Brenda and Lahijanian, Zubin and Eddin, Anas Hussam and Mallick, Ranjeeta and Ramsay, Tim and Rosenfeld, Greg and Bessissow, Ali and Bessissow, Talat and Jairath, Vipul and Singh, Siddharth and Bruining, David H and Macdonald, Blair and Canadian IBD Research Consortium, Canadian IBD Research Consortium},
  title = {Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2023.12.006}
}
Kostenlos starten →